- Home
- AMSF vs CGEM Comparison
AMSF vs CGEM Comparison
Compare AMSF & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | CGEM |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | 109 |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.4M | 1.4B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMSF | CGEM |
|---|---|---|
| Price | $24.47 | $19.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $46.33 | $30.13 |
| AVG Volume (30 Days) | 367.3K | ★ 754.4K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $317,252,000.00 | N/A |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $6.03 | $5.20 |
| P/E Ratio | $20.30 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $24.11 | $5.68 |
| 52 Week High | $44.66 | $23.19 |
Technical Indicators
Market Signals| Indicator | AMSF | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.